What's New

Last Posted: Nov 01, 2024

• Combination therapy with BRAF and MEK inhibitors for anaplastic thyroid cancer: A report of two cases.
  Mayu Yamauchi, et al. Auris, nasus, larynx 2024 0 (6) 1003-1008
• Efficacy and safety of BRAF/MEK inhibitors in BRAFV600E-mutated anaplastic thyroid cancer: a systematic review and meta-analysis.
  Jonathan N Priantti, et al. Endocrine 2024 0
• Combination BRAFV600E inhibition with the multitargeting tyrosine kinase inhibitor axitinib shows additive anticancer activity in BRAFV600E-mutant anaplastic thyroid cancer.
  Viswanath Gunda, et al. Thyroid : official journal of the American Thyroid Association 2023 0
• Molecular genetics of diffuse sclerosing papillary thyroid cancer.
  Alswailem Meshael, et al. The Journal of clinical endocrinology and metabolism 2023 0
• Anaplastic Thyroid Cancer in Sicily: The Role of Environmental Characteristics.
  Tavarelli Martina, et al. Frontiers in endocrinology 2017 0 277
• GPCR-mediated PI3K pathway mutations in pediatric and adult thyroid cancer.
  Murugan Avaniyapuram Kannan, et al. Oncotarget 2019 0 (41) 4107-4124
• Everolimus in Anaplastic Thyroid Cancer: A Case Series.
  Harris Ethan J, et al. Frontiers in oncology 2019 0 106
• Identification of Targetable Lesions in Anaplastic Thyroid Cancer by Genome Profiling.
  Ravi Naveen, et al. Cancers 2019 0 (3)
• EIF1AX c.338-2A>T splice site mutation in a patient with trabecular adenoma and cytological indeterminate lesion.
  Castagna Maria Grazia, et al. Archives of endocrinology and metabolism 2020 0 (2) 185-189
• Analysis of ALK, IDH1, IDH2 and MMP8 somatic mutations in differentiated thyroid cancers.
  Murugan Avaniyapuram Kannan, et al. Molecular and clinical oncology 2021 0 (4) 210
• Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study.
  Hanna Glenn J, et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2018 0 (7) 1546-1553
• Impact of tumor-associated macrophages and BRAF mutation on clinical outcomes in patients with various thyroid cancers.
  Cho Jae Won, et al. Head & neck 2019 0 (3) 686-691
• Dedifferentiation patterns in DTC: is PDTC an intermediate state between DTC and ATC?
  Wen Duo, et al. International journal of clinical and experimental pathology 2020 0 (1) 267-274
• Clinical Application of Next-Generation Sequencing in Advanced Thyroid Cancers.
  Ma Lucy X et al. Thyroid : official journal of the American Thyroid Association 2022
• Poorly Differentiated and Anaplastic Thyroid Cancer: Insights into Genomics, Microenvironment and New Drugs.
  Prete Alessandro et al. Cancers 2021 13(13)
• Novel Recurrent Altered Genes in Chinese Patients With Anaplastic Thyroid Cancer.
  Zhang Lingyun, et al. The Journal of clinical endocrinology and metabolism 2021 1
• The mutation profile of differentiated thyroid cancer coexisting with undifferentiated anaplastic cancer resembles that of anaplastic thyroid cancer but not that of archetypal differentiated thyroid cancer.
  Mika Justyna, et al. Journal of applied genetics 2020 11
• Genomic amplification of long noncoding RNA HOTAIRM1 drives anaplastic thyroid cancer progression via repressing miR-144 biogenesis.
  Zhang Ling et al. RNA biology 2020 Sep 1-16
• TERT promoter mutations and long-term survival in patients with thyroid cancer.
  Kim Tae Hyuk, et al. Endocrine-related cancer 2016 0 (10) 813-23
• Not the same thing: metastatic PTCs have a different background than ATCs.
  de Biase Dario, et al. Endocrine connections 2018 11
• The role of TERT promoter mutations in postoperative and preoperative diagnosis and prognosis in thyroid cancer.
  Jin Anqi et al. Medicine 2018 Jul 97(29) e11548
• Diagnostic value and lymph node metastasis prediction of a custom‑made panel (thyroline) in thyroid cancer.
  Ke Zunfu et al. Oncology reports 2018 Jun
• Diagnostic value and lymph node metastasis prediction of a custom?made panel (thyroline) in thyroid cancer.
  Ke Zunfu, et al. Oncology reports 2018 6
• Increased Global DNA Hypomethylation in Distant Metastatic and Dedifferentiated Thyroid Cancer.
  Klein Hesselink Esther N, et al. The Journal of clinical endocrinology and metabolism 2017 11
• Clinicopathological characteristics of thyroid cancer in the federal state of Salzburg.
  Rendl Gundula, et al. Wiener klinische Wochenschrift 2017 5
• Association of telomerase reverse transcriptase promoter mutations with clinicopathological features and prognosis of thyroid cancer: a meta-analysis.
  Su Xingyun, et al. OncoTargets and therapy 2016 0 6965-6976
• Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial.
  Schneider T C, et al. The Journal of clinical endocrinology and metabolism 2016 11 jc20162525
• Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.
  Latteyer Soeren, et al. Endocrine 2016 10
• Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
  Hyman David M, et al. The New England journal of medicine 2015 8 (8) 726-36
• Anaplastic thyroid cancer: outcome and the mutation/expression profiles of potential targets.
  Wu Hao, et al. Pathology oncology research : POR 2015 7 (3) 695-701
• Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer.
  Shi Xiaoguang, et al. The Journal of clinical endocrinology and metabolism 2015 4 (4) E632-7
• Germline alterations in RASAL1 in Cowden syndrome patients presenting with follicular thyroid cancer and in individuals with apparently sporadic epithelial thyroid cancer.
  Ngeow Joanne, et al. The Journal of clinical endocrinology and metabolism 2014 7 (7) E1316-21
• Thyroid Cancer—Patient Version
  
• Identification of RASAL1 as a major tumor suppressor gene in thyroid cancer.
  Liu Dingxie, et al. Journal of the National Cancer Institute 2013 11 (21) 1617-27
• Mutational analysis of the GNA11, MMP27, FGD1, TRRAP and GRM3 genes in thyroid cancer.
  Murugan Avaniyapuram Kannan, et al. Oncology letters 2013 8 (2) 437-441
• Circulating cell-free DNA, SLC5A8 and SLC26A4 hypermethylation, BRAF(V600E): A non-invasive tool panel for early detection of thyroid cancer.
  Zane Mariangela, et al. Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2013 10 (8) 723-30
• Anaplastic thyroid cancer
  From NCATS Genetic and Rare Diseases Information Center